GT Biopharma Inc expected to post a loss of 64 cents a share - Earnings Preview

GT Biopharma

09/05/2025 23:18

GT Biopharma Inc GTBP.OQ GTBP.O is expected to show no change in quarterly revenue when it reports  results on May 13 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for GT Biopharma Inc is for a loss of 64 cents per share.

The one available analyst rating on the shares is "buy".

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for GT Biopharma Inc is $11.00​, above​ its last closing price of $2.27. ​​​

This summary was machine generated May 9 at 22:18 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)